juvenile myelomonocytic leukemia (Cancer)
Information
- Disease name
- juvenile myelomonocytic leukemia
- Disease ID
- DOID:0050458
- Description
- "A myelodysplastic/myeloproliferative neoplasm that is characterized by the uncontrolled growth of monocytes." [url:https\://rarediseases.org/rare-diseases/juvenile-myelomonocytic-leukemia/]
Disease area statistics
Chromosome band
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02338479 | Active, not recruiting | Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies | March 2015 | December 2023 | |
| NCT03190915 | Active, not recruiting | Phase 2 | Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia | September 9, 2018 | September 22, 2024 |
| NCT05515029 | Active, not recruiting | Phase 3 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis | August 23, 2022 | October 16, 2026 |
| NCT00662090 | Active, not recruiting | Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood | January 2006 | December 2024 | |
| NCT00112593 | Completed | N/A | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | November 1999 | |
| NCT00118352 | Completed | Phase 2 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | March 2005 | May 26, 2015 |
| NCT00143559 | Completed | Phase 2 | Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies | August 2005 | January 2009 |
| NCT00152139 | Completed | Phase 3 | Stem Cell Transplantation for Patients With Hematologic Malignancies | May 2002 | January 2009 |
| NCT00167219 | Completed | Phase 1/Phase 2 | Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) | November 18, 1999 | August 9, 2023 |
| NCT00217412 | Completed | Phase 1 | Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia | August 2005 | September 2009 |
| NCT00006251 | Completed | Phase 1/Phase 2 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | May 2000 | |
| NCT00408681 | Completed | N/A | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant | June 2006 | May 1, 2015 |
| NCT00450450 | Completed | Phase 3 | Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | December 31, 2007 | March 31, 2022 |
| NCT00489203 | Completed | Phase 2 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | April 2007 | |
| NCT00697671 | Completed | Phase 1 | Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies | March 2007 | May 2013 |
| NCT00856388 | Completed | N/A | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | January 14, 2009 | March 13, 2019 |
| NCT00898079 | Completed | Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer | October 13, 2003 | June 30, 2018 | |
| NCT01020539 | Completed | Phase 1 | Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia | September 11, 2002 | December 2020 |
| NCT01036009 | Completed | Phase 2 | A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies | October 2009 | July 2015 |
| NCT01053494 | Completed | N/A | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | April 2010 | February 2012 |
| NCT01093586 | Completed | Phase 2 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | September 2007 | December 2015 |
| NCT01231919 | Completed | Phase 1 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | January 2011 | |
| NCT01305200 | Completed | Phase 3 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | March 2011 | June 30, 2015 |
| NCT01384513 | Completed | Phase 2 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | August 4, 2011 | November 16, 2022 |
| NCT01445080 | Completed | Phase 1/Phase 2 | Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | May 30, 2006 | December 10, 2012 |
| NCT01529827 | Completed | Phase 2 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | February 28, 2012 | August 29, 2019 |
| NCT00309907 | Completed | Phase 2 | Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant | April 2006 | September 2011 |
| NCT00014235 | Completed | N/A | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | December 2000 | |
| NCT00025038 | Completed | Phase 2 | Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia | June 2001 | |
| NCT00078858 | Completed | Phase 1/Phase 2 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | September 2003 | |
| NCT01824693 | Completed | Phase 2 | Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia | June 24, 2013 | December 31, 2017 |
| NCT02458235 | Completed | Phase 2 | Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation | June 2, 2015 | March 15, 2019 |
| NCT04082286 | Completed | Phase 1 | Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia | May 2016 | May 14, 2020 |
| NCT04024761 | Enrolling by invitation | Phase 1 | A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation | August 31, 2019 | December 1, 2024 |
| NCT05735717 | Recruiting | Phase 2 | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | May 11, 2023 | November 30, 2030 |
| NCT03314974 | Recruiting | Phase 2 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | March 30, 2018 | November 10, 2025 |
| NCT03810196 | Recruiting | N/A | CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT | March 1, 2019 | January 2026 |
| NCT03843528 | Recruiting | Phase 1 | Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | May 1, 2019 | October 30, 2024 |
| NCT05800210 | Recruiting | Phase 2 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | May 3, 2024 | May 2027 |
| NCT04726241 | Recruiting | Phase 1/Phase 2 | The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | April 18, 2022 | December 31, 2026 |
| NCT03326921 | Suspended | Phase 1 | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | February 23, 2018 | July 16, 2028 |
| NCT00852709 | Terminated | Phase 1 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias | September 1, 2007 | November 20, 2009 |
| NCT00669890 | Terminated | Phase 1 | Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML | May 2004 | December 2013 |
| NCT01621477 | Terminated | Phase 2 | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | August 2012 | December 2015 |
| NCT01339988 | Unknown status | Phase 4 | Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) | June 2011 | June 2019 |
| NCT02564536 | Withdrawn | Phase 1 | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | June 2017 | June 30, 2020 |
- Disase is a (Disease Ontology)
- DOID:4972
- Cross Reference ID (Disease Ontology)
- GARD:9884
- Cross Reference ID (Disease Ontology)
- ICD10CM:C93.3
- Cross Reference ID (Disease Ontology)
- ICDO:9946/3
- Cross Reference ID (Disease Ontology)
- MESH:D054429
- Cross Reference ID (Disease Ontology)
- MIM:607785
- Cross Reference ID (Disease Ontology)
- NCI:C9233
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:445227008
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0349639
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0012209